- Conditions
- Obesity, Overweight
- Interventions
- NNC0487-0111, Placebo (NNC0487-0111)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 27,150
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Back Pain, Neck Pain, Sleep Initiation and Maintenance Disorders
- Interventions
- Magnetic Sleep Pad
- Device
- Lead sponsor
- Weintraub, Michael I., MD, FACP, FAAN
- Individual
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Briarcliff Manor, New York
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Interventions
- Bimekizumab, Ustekinumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
- Conditions
- Parkinson Disease
- Interventions
- L-DOPS, Placebo
- Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 30 Years to 83 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Urinary Retention Postoperative
- Interventions
- Uroselective alpha-1-adrenergic receptor antagonist, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Generalized Anxiety Disorder
- Interventions
- Quetiapine fumarate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 876 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 58
- States / cities
- Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more
- Conditions
- Lung Cancer - Non Small Cell Squamous
- Interventions
- Ipilimumab, Placebo, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 33
- States / cities
- San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
- Conditions
- New-onset Type 1 Diabetes Mellitus
- Interventions
- Antithymocyte globulin, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 6 more
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- SLS-005, Placebo
- Drug
- Lead sponsor
- Seelos Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
- Conditions
- Obstructive Sleep Apnea of Adult
- Interventions
- Atorvastatin 10mg, Placebo, Continuous Positive Airway Pressure Therapy
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head And Neck Cancer
- Interventions
- Minocycline, Placebo, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bulimia Nervosa, Eating Disorders
- Interventions
- Erythromycin, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Alcoholic Fatty Liver Disease, NAFLD, Pediatric NAFLD
- Interventions
- Empagliflozin 10 MG, Placebo Oral Tablet
- Drug
- Lead sponsor
- Justin Ryder
- Other
- Eligibility
- 12 Years to 20 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Primary Hyperoxaluria Type 1, PH1
- Interventions
- YOLT-203, Placebo
- Genetic · Drug
- Lead sponsor
- YolTech Therapeutics Co., Ltd
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Aurora, Colorado • St Louis, Missouri + 1 more
- Conditions
- Fibrodysplasia Ossificans Progressiva
- Interventions
- Andecaliximab, Placebo
- Drug
- Lead sponsor
- Ashibio Inc
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- West Nile Viral Infection
- Interventions
- HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 2, Renal Insufficiency
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 26
- States / cities
- Concord, California • Fountain Valley, California • San Diego, California + 23 more
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Placebo Administration, Selinexor, Temozolomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Duarte, California • Irvine, California + 32 more
- Conditions
- Smoking Cessation
- Interventions
- placebo, Varenicline
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Madison, Wisconsin
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Pasadena, California • Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Pioglitazone 45 mg, Placebo
- Drug
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
- Interventions
- Bimekizumab, Adalimumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 23
- States / cities
- Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Avondale, Arizona • Peoria, Arizona • Phoenix, Arizona + 17 more